Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Muriel Aguilar-Bretones; Brenda M. Westerhuis; Matthijs P. Raadsen; Erwin de Bruin; Felicity D. Chandler; Nisreen M.A. Okba; Bart L. Haagmans; Thomas Langerak; Henrik Endeman; Johannes P. C. van den Akker; Diederik Gommers; Eric C. M. van Gorp; Corine H. GeurtsvanKessel; Rory D. de Vries; Ron A. M. Fouchier; Barry Rockx; Marion Koopmans; Gijsbert P. van Nierop

Journal title: Journal of Clinical Investigation

Journal number: 51

Journal publisher: American Society for Clinical Investigation

Published year: 2021

DOI identifier: 10.1172/jci150613

ISSN: 1558-8238